Digital Obesity Treatment Platforms & GLP-1 Telehealth Market
完整報告名稱與涵蓋範圍
Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Size, Share & Trends Analysis Report, By Platform Type (Direct-to-Consumer GLP-1 Telehealth and Prescribing Platforms, Employer and Payer-Sponsored Digital Obesity Programs, Digital Weight Management and Behavioral Coaching Platforms, Compounded and Specialty Pharmacy Fulfillment Integrated Services), By Service Component (Virtual Clinical Consultations and Prescribing, Medication Fulfillment and Delivery, Behavioral, Nutrition and Adherence Support, Remote Monitoring and Data Integration), By End User (Consumers and Self-Pay Patients, Employers and Health Plans, Health Systems and Providers), By Region, and Segment Forecasts, 2026-2035
報告摘要
The digital obesity treatment platforms and GLP-1 telehealth market covers direct-to-consumer telehealth platforms that prescribe and deliver incretin and other obesity medications, employer and payer-sponsored digital obesity programs, digital weight management and behavioural coaching platforms and integrated pharmacy fulfillment services, spanning virtual consultation, medication delivery, coaching and remote monitoring. The obesity drugs themselves are excluded from revenue except where platforms capture pharmacy margin, and in-person obesity medicine practices are analysed as the traditional care alternative.
The category expanded rapidly as demand for incretin therapies outstripped clinic capacity, as compounded versions filled supply shortages and as consumers sought discreet, convenient access, creating multi-billion-dollar telehealth franchises within a few years. Pharmaceutical manufacturers have responded with direct-to-patient channels and cash-pay pricing, regulators have tightened rules on compounding and advertising as shortages resolved and employers and payers are turning to structured programs that combine medication with behavioural support to manage cost and outcomes. Platforms compete on clinical protocols, medication access and pricing, adherence support, integration with employer benefits and the ability to manage long-term maintenance and discontinuation, while margins depend on drug supply agreements and the compounding regulatory environment.
North America dominates, with the United Kingdom, Australia and parts of Europe developing telehealth obesity services and Asia Pacific in early stages. Competition involves consumer telehealth brands, weight management incumbents, employer-focused digital health companies and pharmaceutical direct-to-patient channels.
The InsightAce study supplies US$ forecasts for all platform type, service component and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Snapshot
Chapter 4. Global Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Platform Type Estimates & Trend Analysis
5.1. Platform Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Platform Type:
5.2.1. Direct-to-Consumer GLP-1 Telehealth and Prescribing Platforms
5.2.2. Employer and Payer-Sponsored Digital Obesity Programs
5.2.3. Digital Weight Management and Behavioral Coaching Platforms
5.2.4. Compounded and Specialty Pharmacy Fulfillment Integrated Services
Chapter 6. Market Segmentation 2: By Service Component Estimates & Trend Analysis
6.1. Service Component & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Service Component:
6.2.1. Virtual Clinical Consultations and Prescribing
6.2.2. Medication Fulfillment and Delivery
6.2.3. Behavioral, Nutrition and Adherence Support
6.2.4. Remote Monitoring and Data Integration
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Consumers and Self-Pay Patients
7.2.2. Employers and Health Plans
7.2.3. Health Systems and Providers
Chapter 8. Digital Obesity Treatment Platforms & GLP-1 Telehealth Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Hims & Hers Health, Inc.
10.2. Ro (Roman Health Ventures Inc.)
10.3. WeightWatchers (WW International, Inc.)
10.4. Noom, Inc.
10.5. Teladoc Health, Inc.
10.6. Omada Health, Inc.
10.7. Found Health, Inc.
10.8. Calibrate Health, Inc.
10.9. Sequence (WeightWatchers)
10.10. LifeMD, Inc.
10.11. Virta Health Corp.
10.12. Form Health, Inc.
10.13. Knownwell
10.14. Novo Nordisk A/S (NovoCare Pharmacy)
10.15. Eli Lilly and Company (LillyDirect)
圖表清單 List of Tables & Figures
Table 1. Global Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Revenue Forecast by Platform Type, 2026-2035 (US$ Mn)
Figure 1. Global Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Segmentation Overview
Table 2. Global Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Revenue Forecast by Service Component, 2026-2035 (US$ Mn)
Figure 2. Global Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Share by Platform Type, 2026 & 2035
Table 3. Global Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. Digital Obesity Care Pathway from Virtual Assessment to Medication Delivery and Maintenance
Table 4. North America Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Global Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Share by Service Component, 2026 & 2035
Table 5. Europe Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Regulatory and Supply Dynamics for Compounded Incretin Therapies, 2023-2027
Table 6. Asia Pacific Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Digital Obesity Treatment Platforms & GLP-1 Telehealth Growth Opportunity Analysis
Table 7. Latin America Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Employer and Payer Program Adoption Versus Direct-to-Consumer Demand, 2026-2035
Table 8. Middle East & Africa Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Digital Obesity Treatment Platforms & GLP-1 Telehealth Market Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們